Clareo Health | A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Avid Radiopharmaceuticals
Age
50–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Male or female \>=50 years of age
Meet National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS) criteria for probable AD with MMSE score of 10-24
Male or female \>=50 years of age
Have a Clinical Dementia Rating (CDR) of 0.5
MMSE \>24
Normal subjects:
Male or female \>=50 years of age
MMSE \>=29
Normal on psychometric test battery at screening
Provide informed consent
You may not be if
Have a history or current diagnosis of other neurologic disease
Have had or currently have a diagnosis of other neurodegenerative disease
Have participated in experimental therapy targeted to amyloid plaque
